GlassScriptPhysician profile
Vito C Proscia
NPI 1972575876
$888.99
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $136 · 2021: $133 · 2022: $17.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.61 | 2019-2021 | |
| Janssen Biotech, INC. | $227.92 | 2019-2022 | |
| Pfizer INC. | $76.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.86 | 2019-2020 | |
| Allergan, INC. | $44.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.82 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $38.54 | 2019 | |
| Ironwood Pharmaceuticals, INC | $20.63 | 2020 | |
| Shire North American Group INC | $19.59 | 2019 | |
| Redhill Biopharma INC. | $18.69 | 2020 | |
| Braintree Laboratories, INC. | $15.58 | 2019 | |
| Merck Sharp & Dohme LLC | $14.01 | 2019 | |
| Celgene Corporation | $12.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vito Proscia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.